Research programme: muscular dystrophy therapeutics - Prothelia/University of Nevada

Drug Profile

Research programme: muscular dystrophy therapeutics - Prothelia/University of Nevada

Alternative Names: Laminin-111; PRT-01; PRT-300; PRT-400; PRT-500

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator University of Nevada Reno
  • Developer Prothelia; University of Nevada Reno
  • Class Proteins; Small molecules
  • Mechanism of Action Integrin modulators; Protein replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Duchenne muscular dystrophy; Muscular dystrophies
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Duchenne muscular dystrophy; Limb girdle muscular dystrophies
  • No development reported Muscular dystrophies

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Muscular-dystrophies in USA
  • 19 Feb 2014 Preclinical trials in Limb girdle muscular dystrophies in USA (unspecified route)
  • 19 Feb 2014 Preclinical trials in Duchenne muscular dystrophy in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top